YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs

INTRODUCTION: ALK tyrosine kinase inhibitors (TKIs) are the standard treatment for advanced ALK-positive NSCLC. Nevertheless, drug resistance inevitably occurs. Here, we report a case of a patient with metastatic ALK-positive lung adenocarcinoma with an impressive resistance to sequential treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Minari, Roberta, Valentini, Samuel, Madeddu, Denise, Cavazzoni, Andrea, La Monica, Silvia, Lagrasta, Costanza Anna Maria, Bertorelli, Roberto, De Sanctis, Veronica, Fassan, Paola, Azzoni, Cinzia, Bottarelli, Lorena, Frati, Caterina, Gnetti, Letizia, Facchinetti, Francesco, Petronini, Pier Giorgio, Alfieri, Roberta, Romanel, Alessandro, Tiseo, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851257/
https://www.ncbi.nlm.nih.gov/pubmed/35199053
http://dx.doi.org/10.1016/j.jtocrr.2022.100278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851257/
https://www.ncbi.nlm.nih.gov/pubmed/35199053
http://dx.doi.org/10.1016/j.jtocrr.2022.100278

Ejemplares similares